Beauty Health (NASDAQ:SKIN) Shares Cross Above 50 Day Moving Average - Should You Sell?

Key Points

• Beauty Health shares rose above their 50-day moving average, trading as high as $15.95 and last at $15.71, above the $12.30 average but below the $16.38 200-day average.
• Analysts maintain a consensus Hold rating, with an average price target of $18.00; the analyst mix is one Buy, six Holds and one Sell.
• The company reported quarterly EPS of -$0.14, beating the -$1.33 consensus estimate, and revenue of $69.17 million, above the $67.97 million estimate.

Shares of The Beauty Health Company (NASDAQ:SKIN - Get Free Report) crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $12.30 and traded as high as $15.95. Beauty Health shares last traded at $15.71, with a volume of 433,975 shares.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Zacks Research cut Beauty Health from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 20th. Canaccord Genuity Group set a $11.00 price target on Beauty Health and gave the company a "hold" rating in a research note on Thursday, October 22nd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Beauty Health in a research report on Wednesday, October 21st. Citigroup reissued a "hold" rating on shares of Beauty Health in a research report on Thursday, October 15th. Finally, Stifel Nicolaus set a $10.00 price objective on shares of Beauty Health in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Beauty Health currently has a consensus rating of "Hold" and an average price target of $18.00.

Beauty Health Price Performance

The firm has a market capitalization of $102.27 million, a price-to-earnings ratio of -5.73 and a beta of 1.05. The company has a quick ratio of 1.48, a current ratio of 1.76 and a debt-to-equity ratio of 4.36. The stock's 50 day moving average price is $12.30 and its two-hundred day moving average price is $16.38.

Beauty Health (NASDAQ:SKIN - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $1.19. The company had revenue of $69.17 million during the quarter, compared to analyst estimates of $67.97 million. Beauty Health had a negative return on equity of 47.83% and a negative net margin of 9.79%. Analysts anticipate that The Beauty Health Company will post -3.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Beauty Health stock. Renaissance Technologies LLC raised its holdings in shares of The Beauty Health Company (NASDAQ:SKIN - Free Report) by 29.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 283,791 shares of the company's stock after acquiring an additional 64,900 shares during the quarter. Renaissance Technologies LLC owned approximately 0.22% of Beauty Health worth $253,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 93.26% of the company's stock.

Beauty Health Company Profile

BeautyHealth is a global health and beauty company focused on providing technology, products and services for aesthetic and skincare businesses. Its flagship brand, HydraFacial, offers a non-invasive treatment platform that combines cleansing, exfoliation, extraction and hydration, with treatments delivered through proprietary devices and consumable solutions.

The company also provides professional skincare products, treatment systems and related solutions designed for use by physicians, dermatologists, aestheticians and other licensed practitioners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.